Equities

FibroGen Inc

FibroGen Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.3866
  • Today's Change0.048 / 14.18%
  • Shares traded3.66m
  • 1 Year change+1.71%
  • Beta0.7435
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments236422405
Total Receivables, Net411625
Total Inventory424031
Prepaid expenses6.649.737.38
Other current assets, total6.714.355.07
Total current assets332493474
Property, plant & equipment, net81101120
Goodwill, net------
Intangibles, net------
Long term investments5.299.41172
Note receivable - long term------
Other long term assets3.654.855.92
Total assets424610774
LIABILITIES
Accounts payable183126
Accrued expenses187230180
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.040.040.01
Other current liabilities, total131319
Total current liabilities218274225
Total long term debt901718
Total debt901718
Deferred income tax----9.19
Minority interest422020
Other liabilities, total278321292
Total liabilities628632565
SHAREHOLDERS EQUITY
Common stock0.990.940.93
Additional paid-in capital1,6441,5411,476
Retained earnings (accumulated deficit)(1842)(1558)(1264)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(6.88)(5.72)(4.16)
Total equity(204)(21)209
Total liabilities & shareholders' equity424610774
Total common shares outstanding999493
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.